Immediate Impact
1 by Nobel laureates 1 from Science/Nature 70 standout
Citing Papers
Lorlatinib Versus Crizotinib in Patients With Advanced ALK -Positive Non–Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study
2024 Standout
Immune checkpoint therapy—current perspectives and future directions
2023 StandoutNobel
Works of K. Park being referenced
HLA-corrected tumor mutation burden and homologous recombination deficiency for the prediction of response to PD-(L)1 blockade in advanced non-small-cell lung cancer patients
2020
A randomized phase III trial of stereotactic radiosurgery (SRS) versus observation for patients with asymptomatic cerebral oligo-metastases in non-small-cell lung cancer
2014
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| K. Park | 468 | 649 | 197 | 222 | 41 | 966 | |
| Hui‐Lan Rao | 216 | 645 | 181 | 289 | 44 | 1.1k | |
| Suk Joong Oh | 408 | 520 | 257 | 253 | 38 | 989 | |
| L.L. Siu | 283 | 805 | 235 | 85 | 30 | 1.1k | |
| J. Feng | 414 | 646 | 209 | 171 | 69 | 985 | |
| Yeu‐Tsu N. Lee | 338 | 609 | 187 | 113 | 56 | 1.0k | |
| J.P. Delord | 274 | 696 | 94 | 82 | 48 | 960 | |
| Ying Zhu | 255 | 662 | 242 | 112 | 27 | 968 | |
| Yuezong Bai | 381 | 601 | 141 | 151 | 57 | 925 | |
| Hao Yu | 556 | 755 | 160 | 120 | 26 | 1.1k | |
| Su Jin Heo | 327 | 545 | 216 | 114 | 38 | 880 |
All Works
Loading papers...